Therapeutic antibodies to intracellular targets in cancer therapy

Abstract

Therapeutic monoclonal antibodies (mAbs) are a proven therapeutic platform, but they cannot readily cross the cell membranes to bind intracellular antigens, while some of the most important disease-associated proteins are intracellular, protected from direct mAb attack. However, the cellular processes of necrosis and major histocompatibility complex (MHC) class I antigen presentation expose epitopes from intracellular proteins to the extracellular environment or cell surface. Antibodies that exploit these processes can therefore specifically target diseased cells based on their intracellular protein content. These strategies expose important new targets for mAb therapy and expand the potential for effective therapies.

Keywords::

• antibody therapy
• ESK1
• HLA
• intracellular antigens
• MHC class I presentation
• TCR mimic
• TCR-like
• tumor necrosis therapy